Literature DB >> 27763886

CYP2B6*6 or Not CYP2B6*6-That Remains a Question for Precision Medicine and Ketamine!

Scott D Cook-Sather1, Peter C Adamson, Jin Li, Hakon Hakonarson.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27763886      PMCID： PMC5123751          DOI： 10.1097/ALN.0000000000001399

Source DB:  PubMed          Journal:  Anesthesiology        ISSN： 0003-3022            Impact factor:   7.892


× No keyword cloud information.
  25 in total

Review 1.  PharmGKB summary: succinylcholine pathway, pharmacokinetics/pharmacodynamics.

Authors:  Maria L Alvarellos; Ellen M McDonagh; Sephalie Patel; Howard L McLeod; Russ B Altman; Teri E Klein
Journal:  Pharmacogenet Genomics       Date:  2015-12       Impact factor: 2.089

Review 2.  Pharmacogenomics in the clinic.

Authors:  Mary V Relling; William E Evans
Journal:  Nature       Date:  2015-10-15       Impact factor: 49.962

Review 3.  Clinical Pharmacogenetics Implementation Consortium guidelines for cytochrome P450-2C19 (CYP2C19) genotype and clopidogrel therapy.

Authors:  S A Scott; K Sangkuhl; E E Gardner; C M Stein; J-S Hulot; J A Johnson; D M Roden; T E Klein; A R Shuldiner
Journal:  Clin Pharmacol Ther       Date:  2011-06-29       Impact factor: 6.875

4.  Exposure to oral S-ketamine is unaffected by itraconazole but greatly increased by ticlopidine.

Authors:  M A Peltoniemi; T I Saari; N M Hagelberg; P Reponen; M Turpeinen; K Laine; P J Neuvonen; K T Olkkola
Journal:  Clin Pharmacol Ther       Date:  2011-06-29       Impact factor: 6.875

Review 5.  Preemptive clinical pharmacogenetics implementation: current programs in five US medical centers.

Authors:  Henry M Dunnenberger; Kristine R Crews; James M Hoffman; Kelly E Caudle; Ulrich Broeckel; Scott C Howard; Robert J Hunkler; Teri E Klein; William E Evans; Mary V Relling
Journal:  Annu Rev Pharmacol Toxicol       Date:  2014-10-02       Impact factor: 13.820

6.  CYP2B6*6 allele and age substantially reduce steady-state ketamine clearance in chronic pain patients: impact on adverse effects.

Authors:  Yibai Li; Kate A Jackson; Barry Slon; Janet R Hardy; Michael Franco; Leeroy William; Peter Poon; Janet K Coller; Mark R Hutchinson; David C Currow; Andrew A Somogyi
Journal:  Br J Clin Pharmacol       Date:  2015-06-01       Impact factor: 4.335

7.  Clinical pharmacogenetics implementation consortium guidelines for CYP2C9 and HLA-B genotypes and phenytoin dosing.

Authors:  K E Caudle; A E Rettie; M Whirl-Carrillo; L H Smith; S Mintzer; M T M Lee; T E Klein; J T Callaghan
Journal:  Clin Pharmacol Ther       Date:  2014-08-06       Impact factor: 6.875

Review 8.  Ketamine: A Review of Clinical Pharmacokinetics and Pharmacodynamics in Anesthesia and Pain Therapy.

Authors:  Marko A Peltoniemi; Nora M Hagelberg; Klaus T Olkkola; Teijo I Saari
Journal:  Clin Pharmacokinet       Date:  2016-09       Impact factor: 6.447

9.  Contribution of CYP3A4, CYP2B6, and CYP2C9 isoforms to N-demethylation of ketamine in human liver microsomes.

Authors:  Youssef Hijazi; Roselyne Boulieu
Journal:  Drug Metab Dispos       Date:  2002-07       Impact factor: 3.922

10.  Genetic variation among 82 pharmacogenes: The PGRNseq data from the eMERGE network.

Authors:  W S Bush; D R Crosslin; A Owusu-Obeng; J Wallace; B Almoguera; M A Basford; S J Bielinski; D S Carrell; J J Connolly; D Crawford; K F Doheny; C J Gallego; A S Gordon; B Keating; J Kirby; T Kitchner; S Manzi; A R Mejia; V Pan; C L Perry; J F Peterson; C A Prows; J Ralston; S A Scott; A Scrol; M Smith; S C Stallings; T Veldhuizen; W Wolf; S Volpi; K Wiley; R Li; T Manolio; E Bottinger; M H Brilliant; D Carey; R L Chisholm; C G Chute; J L Haines; H Hakonarson; J B Harley; I A Holm; I J Kullo; G P Jarvik; E B Larson; C A McCarty; M S Williams; J C Denny; L J Rasmussen-Torvik; D M Roden; M D Ritchie
Journal:  Clin Pharmacol Ther       Date:  2016-06-01       Impact factor: 6.875
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.